Understanding rs755416212: A Rare Pharmacogenomic Variant
The rs755416212 variant is a rare genetic change located in an intergenic region of the human genome. It is currently monitored in clinical pharmacogenomics databases due to its potential, though not yet fully established, influence on how individuals process or respond to specific medications.
What each genotype means
Common reference genotype
This genotype represents the most frequently observed sequence at this location in the human genome. It is considered the baseline state, and there is no evidence suggesting this specific sequence influences drug response or clinical outcomes. You should not make any changes to your medical care based on this result.
This is the predominant genotype found in nearly all global populations.
Rare variant carrier
You carry one copy of a rare genetic variant at this position. Because this variant is rare and evidence regarding its clinical significance is limited, its potential impact on drug metabolism or therapeutic response remains uncertain. Please discuss this finding with your clinician or pharmacist to determine if it has any relevance to your specific health profile.
This genotype is extremely rare, appearing in a very small fraction of the global population.
Rare homozygous variant
You carry two copies of this rare genetic variant. Current scientific literature provides limited evidence on the functional consequences of this genotype, and it is not currently used to guide clinical decision-making. As with any genetic finding, you should consult with a healthcare professional to interpret this in the context of your overall medical history.
This genotype is exceptionally rare and is observed in a negligible percentage of the population.
What is rs755416212?
The rs755416212 variant is a single nucleotide polymorphism (SNP), which is a variation at a single position in the DNA sequence. This specific variant is classified as intergenic, meaning it is located in the DNA segments between genes rather than within the protein-coding regions themselves. While intergenic regions were once considered 'junk DNA,' modern research has shown that these areas often contain regulatory elements that control when and how genes are turned on or off. Because rs755416212 is tracked in pharmacogenomics—the study of how genes affect a person's response to drugs—researchers are interested in whether this specific location might influence the expression of nearby genes involved in drug metabolism or transport. However, because it does not sit directly inside a gene, its functional impact remains a subject of ongoing investigation rather than established clinical fact.
The Role of Pharmacogenomics
Pharmacogenomics aims to understand how an individual's unique genetic makeup influences their response to medications. By identifying genetic variants that affect drug efficacy or the risk of adverse side effects, clinicians hope to move toward more personalized prescribing practices. Many well-known pharmacogenomic variants are found within genes that encode enzymes responsible for breaking down drugs, such as the cytochrome P450 family. When a variant like rs755416212 is identified as a candidate for study, it is often because preliminary data or computational models suggest it might be linked to a drug-response phenotype. It is important to note that the presence of a variant does not automatically mean a person will have a different drug response. Many factors, including age, diet, liver function, and other medications, play significant roles in how a drug works in the body.
Evidence and Research Status
The current evidence supporting a clinical role for rs755416212 is limited. In the world of genomics, 'limited' means that while the variant is being tracked in databases, there is not yet enough peer-reviewed, clinical-grade evidence to support using this information to make specific medical decisions. Research into such rare variants is challenging because they appear so infrequently in the general population that it is difficult to gather large enough study groups to prove a statistically significant association with a specific drug response. While some variants are well-characterized and used in clinical guidelines, rs755416212 remains in the exploratory phase. Scientists continue to aggregate data from large-scale population studies to determine if this variant has any meaningful impact on human health or medication outcomes. As of now, it is not used in standard clinical testing or routine medical practice.
What You Can Do With This Information
If you have received a report mentioning rs755416212, it is essential to understand that this information is currently for educational and research purposes only. Because the evidence is limited, this variant should not be used to guide changes to your current medication regimen. Never stop or alter the dosage of a prescribed medication based on genetic findings without first consulting your healthcare provider. If you are concerned about how you respond to a specific drug, the best course of action is to have an open conversation with your doctor or a clinical pharmacist. They can evaluate your medical history, current symptoms, and overall health to determine the best treatment plan. Genetic information is only one piece of a much larger puzzle, and clinical judgment remains the most important factor in managing your health and medication safety.
How common is this variant?
The rs755416212 variant is considered rare across global populations, with the vast majority of individuals carrying the common C allele.
Frequently asked questions
Is rs755416212 a dangerous mutation?
No, rs755416212 is not classified as a dangerous mutation. It is a rare genetic variant, and there is currently no evidence suggesting it causes disease or poses a health risk.
Should I change my medication based on this variant?
Absolutely not. You should never change your medication or dosage based on genetic findings without consulting your doctor or pharmacist, as the evidence for this variant is not sufficient for clinical decision-making.
Why is this variant in my genetic report?
Genetic testing companies often include variants that are being studied in research databases. Its inclusion does not imply that it has a known effect on your health or drug response.
Where can I find more information about this SNP?
You can look up the variant on public databases like the NCBI dbSNP website or ClinVar. These resources provide technical data on the variant's location and any associated research studies.
Sources & further reading
Educational information only, last refreshed 9/22/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs755416212?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2D6
This missense variant (A237S) is a known marker used in the definition of specific CYP2D6 star alleles, which influence the metabolism of various drugs including antidepressants and opioids.
This stop-gain variant (R378X) results in a non-functional CYP2D6 enzyme, contributing to a poor metabolizer phenotype that necessitates dosage adjustments for affected medications.
This variant is a key marker for the CYP2D6*10 allele, which results in reduced enzymatic activity and altered metabolism of various psychiatric and analgesic medications.
This variant defines the CYP2D6*4 non-functional allele, which causes impaired metabolism of numerous clinically prescribed medications including antidepressants, tamoxifen, and codeine.
Defines the CYP2D6*17 allele (p.Thr107Ile), which exhibits reduced enzyme activity towards substrates like codeine and certain antidepressants.
Defines the CYP2D6*29 variant (p.Val338Met) conferring decreased metabolic capacity, primarily observed in populations of African descent.